The primary objective of the study is the evaluation of efficacy of a mouthwash cointaining Chlorexidine (CHX) 0.09% + HA + Citrox (test group) on the quality of wound healing and the presence plaque formation and gingival inflammation in the post-surgical phase. Futhermore stains, discolorations and adverse effects will be eventually recorded. Control group will be represented by the use of a CHX 0.12% mouthwash.

Inclusion Criteria:

• More than 20 natural teeth excluding the third molars
• Clinical indication for a surgical intervention for the treatment of at least one residual pocket after non-surgical therapy (pocket depth (PD) ≥5mm)
• Have a full mouth plaque score (FMPS) <15% before surgery;
• Have a full mouth bleeding score (FMBS) <15% before surgery;
• Ability and willingness to give written informed consent;
• Written agreement to participate in the trial.

Exclusion Criteria:

• Use of medications, such as anti-platelet or anti-coagulant agents, any other concomitant systemic disorder, cardiovascular and diabetes diseases, allergic, infectious diseases and medications affecting periodontal inflammation
• Pregnancy or breastfeeding;
• Use of medication affecting the healing process;
• Assumption of systemic or local antibiotics in the 4 weeks before trial beginning;
• Conditions of the teeth or of the site that contraindicate the surgery (severe mobility, fractures, untreated endodontic lesions, incongruous restorations);
• Patients with previous periodontal treatment or who were undergoing a course of dental or orthodontic treatment will be also excluded.
• Tobacco use (10 or more cigarettes per day)
• Inability to comply with protocol
• Uncooperative patient